FGFR1 and neoplasm: GZD824 exhibited strong dose‐dependent antitumor efficacy with tumor growth inhibition (TGI) values of 76.5%, 49.8%, and 73.4% at dosages of 20 mg/kg (Bid) in Ba/F3‐FGFR1, Ba/F3‐FGFR1‐V561M, and Ba/F3‐FGFR1‐V561F, respectively (Figure 5A, 5B, and 5C).